Voriconazole plasma levels in children are highly variable

  • I. Spriet
  • K. Cosaert
  • M. Renard
  • A. Uyttebroeck
  • I. Meyts
  • M. Proesmans
  • G. Meyfroidt
  • J. de Hoon
  • R. Verbesselt
  • L. Willems
Brief Report

Notes

Transparency Declaration

None to declare.

References

  1. 1.
    Cohen-Wolkowiez M, Maan C, Benjamin DK Jr et al (2009) Pediatric antifungal agents. Curr Opin Infect Dis 22:553–558CrossRefPubMedGoogle Scholar
  2. 2.
    Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211CrossRefPubMedGoogle Scholar
  3. 3.
    Andes D, Pascual A, Marchetti O (2009) Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 53:23–34Google Scholar
  4. 4.
    Walsh TJ, Karlsson MO, Driscoll T et al (2004) Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple dose administration. Antimicrob Agents Chemother 48:2166–2172CrossRefPubMedGoogle Scholar
  5. 5.
    Karlsson MO, Lutsar I, Miligan PA (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935–944CrossRefPubMedGoogle Scholar
  6. 6.
    Neely M, Rushing T, Kovacs A et al (2010) Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27–36CrossRefPubMedGoogle Scholar
  7. 7.
    Van der Linden JWM, Bruggeman RJM, Knoop J et al (2009) Therapeutic drug monitoring of voriconazole in pediatric patients. Mycoses 52(Suppl 1):23Google Scholar
  8. 8.
    Spriet I, Annaert P, Meersseman P et al (2009) Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63:767–770CrossRefPubMedGoogle Scholar
  9. 9.
    Purkins L, Wood N, Ghahramani P et al (2002) Pharmacokinetics and safety of voriconazole following intravenous to oral dose escalation regimens. Antimicrob Agents Chemother 46:2546–2553CrossRefPubMedGoogle Scholar
  10. 10.
    Yanni SB, Annaert PP, Augustijns P et al (2010) In vitro hepatic metabolism explains higher clearance of voriconazoel in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Disp 38:25CrossRefGoogle Scholar
  11. 11.
    Vfend EMEA, European Assessment Report. Available from: http://www.ema.europa.eu/humandocs/PDFs/EPAR/vfend/404901en8.pdf. Accessed 29 January 2010
  12. 12.
    Malani AN, Aronoff DM (2008) Voriconazole-induced photosensitivity. Clin Med Res 6:83–85CrossRefPubMedGoogle Scholar
  13. 13.
    Purkins L, Wood N, Ghahramani P, Love ER, Eve MD, Fielding A (2003) Co-administration of voriconazole and phenytoin: pharmacokinetic interaction, safety and toleration. Br J Clin Pharmacol 56(S1):37–44CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • I. Spriet
    • 1
  • K. Cosaert
    • 1
  • M. Renard
    • 2
  • A. Uyttebroeck
    • 2
  • I. Meyts
    • 3
  • M. Proesmans
    • 4
  • G. Meyfroidt
    • 5
  • J. de Hoon
    • 6
  • R. Verbesselt
    • 6
  • L. Willems
    • 1
  1. 1.Pharmacy DepartmentUniversity Hospitals LeuvenLeuvenBelgium
  2. 2.Pediatric OncologyUniversity Hospitals LeuvenLeuvenBelgium
  3. 3.Pediatric ImmunodeficienciesUniversity Hospitals LeuvenLeuvenBelgium
  4. 4.Pediatric PneumologyUniversity Hospitals LeuvenLeuvenBelgium
  5. 5.Surgical Intensive Care UnitUniversity Hospitals LeuvenLeuvenBelgium
  6. 6.Centre for Clinical PharmacologyUniversity Hospitals LeuvenLeuvenBelgium

Personalised recommendations